Artificial intelligence and big data are poised to address the complexity of metabolic diseases, drawing out specific genetic and environmental factors that can inform discovery and development of new therapies and providing the means to modify behaviours which underlie those conditions.
“These tools are starting to come into play and we are optimistic it will start to yield therapies,” said Iain Wilcox, investment advisor at French venture capital firm Seventure Partners. “Many years have been spent trying to unpick these conditions with limited success. The dream is that AI and big data will start to shed light on genes and environmental factors,” Wilcox told delegates at Biotrinity 2019.
Exscientia is at the forefront of artificial intelligence (AI)-driven drug discovery and design. Frontier IP Group plc (LON:FIPP) as a 5% holding in Exscientia as of 30th June 2016.